REGN EBITDA Growth
Regeneron Pharmaceuticals · EBITDA Growth
REGN EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported6.06%period ending
REGN TTM EBITDA YoY % (-66.67% → 6.06%)
Year-over-year change
High-resolution chart · PNG
REGN ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| 6.0592% | |
| 3.9293% | |
| 9.4058% | |
| 3.8241% | |
| 6.1499% | |
| 21.5226% | |
| 13.3105% | |
| 13.2871% | |
| -2.5361% | |
| -10.5661% | |
| -10.767% | |
| -24.2269% | |
| -21.7363% | |
| -46.3678% | |
| -45.6052% | |
| -23.5009% | |
| -11.4126% | |
| 101.4552% | |
| 135.6527% | |
| 123.2514% | |
| 116.0625% | |
| 68.386% | |
| 53.7009% | |
| 53.4861% | |
| 52.4467% | |
| 3.2906% | |
| -2.2101% | |
| -5.9188% | |
| -9.2875% | |
| 12.8012% | |
| 21.3791% | |
| 28.3922% | |
| 39.8636% | |
| 53.9123% | |
| 56.9162% | |
| 53.7134% | |
| 35.375% | |
| 13.0045% | |
| 8.0256% | |
| 1.0827% | |
| 22.9778% | |
| 43.4524% | |
| 54.3622% | |
| 52.7317% | |
| 20.1954% | |
| 14.867% | |
| 7.0905% | |
| 16.0345% | |
| 29.1758% | |
| 33.2373% | |
| 61.6063% | |
| 141.6881% | |
| 1,547.161% | |
| 690.9164% | |
| 391.2513% | |
| 319.7341% | |
| 136.7153% | |
| -26.4779% | |
| -126.2755% | |
| -32.1886% | |
| -52.9061% | |
| -21.5926% | |
| -19.3472% | |
| -90.8193% | |
| -1.7973% | |
| 11.0597% | |
| 12.842% | |
| 1.0084% | |
| -0.332% | |
| 8.6871% | |
| 29.6377% | |
| 55.446% | |
| 34.5316% | |
| 19.6751% | |
| -10.6423% | |
| -177.656% | |
| -173.3306% | |
| -172.3288% | |
| -166.5092% | |
| 312.5524% | |
| 397.0644% | |
| 536.6177% | |
| 851.0297% | |
| -1,155.9147% | |
| -147.0303% | |
| 11.6996% | |
| 116.7393% | |
| 94.4248% | |
| 81.8113% | |
| 67.347% | |
| 22.5595% | |
| 0.9595% | |
| -15.0809% | |
| -30.1949% | |
| -42.5772% | |
| -81.0517% | |
| -91.0163% | |
| -130.6377% | |
| -141.6844% | |
| -144.8092% |